Perimenopause is receiving more public attention, but recognizing it while it is happening remains surprisingly difficult. In a 2025 Pew Research Center survey, 32% of American women in their 40s and 50s said they heard about menopause symptoms extremely or very often, while 27% of women aged 40–59 said they rarely or never heard about them. A 2026 study of 7,640 U.S. women aged 35 years and older found a different form of uncertainty: 34% were unsure of their reproductive stage, rising to 42% among women aged 40–44 years.
Some of that uncertainty is built into the biology. The menopausal transition does not begin with a single event that can be marked on a calendar. Reproductive aging develops progressively as the ovarian follicle pool declines and menstrual-cycle patterns begin to change. Ovarian hormone production also does not decline along a smooth trajectory. Follicle development and ovulation become increasingly variable, follicle-stimulating hormone rises, and estradiol concentrations can fluctuate substantially before eventually settling at the persistently lower concentrations of postmenopause.
The effects can therefore appear in places that initially seem unrelated. Changes in menstrual bleeding can occur alongside hot flashes and night sweats, disturbed sleep, altered mood, vaginal and sexual symptoms, and other changes that emerge at different times and with very different severity from one woman to another. Even one of the most recognizable features of menopause can occupy far more of midlife than commonly assumed: among women in the Study of Women’s Health Across the Nation who experienced frequent vasomotor symptoms, the median duration was 7.4 years, while women whose symptoms began during premenopause or early perimenopause experienced them for a median of more than 11.8 years.
Other changes proceed even when they cannot be felt directly. Longitudinal SWAN data showed that at the beginning of the menopausal transition, the rate of fat-mass gain approximately doubled while lean mass began to decline, with both trajectories continuing until about two years after the final menstrual period. Bone follows its own timetable: bone mineral density loss becomes detectable before menstruation has stopped, accelerates around the final menstrual period, and remains elevated into early postmenopause. Cardiovascular biology also changes across this interval, with the menopausal transition associated with adverse changes in lipids, body-fat distribution, metabolic health, and vascular measures that contribute to the increase in cardiovascular risk seen after menopause.
These changes are connected by more than their timing. Ovarian hormones influence bone turnover, vascular signaling, energy metabolism, skeletal muscle, and the nervous system, so changing hormone exposure alters the conditions under which those tissues continue to function and adapt. But hormone concentration is only part of what determines the eventual response. Bone loss, vascular dysfunction, metabolic change, and impaired recovery also depend on processes such as inflammatory signaling, redox regulation, mitochondrial function, nitric-oxide availability, and cellular remodeling. Perimenopause therefore creates a changing hormonal environment, while the consequences depend partly on how individual tissues respond within that environment.
Those downstream responses are also where molecular hydrogen (H₂) has begun to show biological effects. H₂ has not been shown to stabilize ovarian hormone fluctuations or change the timing of menopause. Instead, experimental and human studies have found changes in several of the same processes that help determine how tissues respond to hormonal and metabolic stress, including inflammatory signaling, redox balance, mitochondrial function, vascular regulation, and tissue remodeling.
Bone provides the most direct connection because H₂ has been studied under experimentally induced estrogen withdrawal. Estrogen loss increases osteoclast formation and bone resorption through pathways that include RANKL, NF-κB, and inflammatory cytokines. In ovariectomized rats, three months of hydrogen-rich water had no significant effect on circulating estrogen, yet it preserved femoral and vertebral bone mineral content and density, trabecular structure, and mechanical strength while reducing oxidative stress and expression of IL-6 and TNF-α in bone. Later work showed that H₂ suppressed RANKL-induced osteoclast formation and NF-κB activation, while hydrogen inhalation preserved trabecular bone and bone mineral density in ovariectomized mice and lowered circulating IL-1β, IL-6, and TNF-α. The estrogen deficit remained, but the processes determining how rapidly bone was lost under that deficit were altered.
The same idea can be carried into metabolism. The menopausal transition is accompanied by increasing fat mass and declining lean mass, while changes in visceral adiposity, lipids, and glucose regulation contribute to the broader cardiometabolic shift of midlife. In a double-blind crossover trial of ten overweight middle-aged women, four weeks of an H₂ intervention reduced body-fat percentage and triglycerides and produced a more favorable fasting-insulin response than placebo. A larger randomized trial in adults with metabolic syndrome found that 24 weeks of hydrogen-rich water reduced fasting glucose, HbA1c, cholesterol, and inflammatory markers while improving several measures of redox balance.
Mitochondrial function may represent one part of that metabolic response. In adults with non-alcoholic fatty liver disease (NAFLD), eight weeks of hydrogen-rich water increased platelet coenzyme Q10 and improved the efficiency of mitochondrial oxidative phosphorylation measured by high-resolution respirometry. NAFLD is biologically different from perimenopause, but the study moves the H₂ evidence beyond circulating oxidative-stress markers and into directly measured human mitochondrial bioenergetics. In tissues already adjusting to changes in body composition, substrate use, and metabolic demand during midlife, that is a more relevant mechanism than simply describing H₂ as an antioxidant.
The vascular findings follow a similar pattern. Endothelial function deteriorates across the menopausal transition, while declining estrogen exposure is associated with reduced nitric-oxide bioavailability and greater oxidative pressure within the vasculature. Randomized studies have found that hydrogen-rich water improved brachial-artery flow-mediated dilation and peripheral reactive hyperemia, providing human evidence that H₂ can influence endothelial responsiveness. The previous estrogen-withdrawal bone experiment also increased endothelial nitric oxide synthase activity and circulating nitric oxide despite leaving estrogen concentrations unchanged, again placing the response downstream of the hormonal deficit.
Sleep is more tentative because the biological connection has not been tested specifically during perimenopause. Four weeks of hydrogen-rich water reduced psychological-distress scores and resting sympathetic activity in a double-blind crossover study, while a randomized trial in people with sleep disorders found that seven days of hydrogen–oxygen inhalation increased total sleep time and sleep efficiency and reduced wake time. These findings make sleep and autonomic regulation reasonable outcomes to investigate in perimenopausal women, but they do not yet show that H₂ reduces menopause-related insomnia, night sweats, or vasomotor symptoms.
Muscle may ultimately be especially important because the menopausal transition begins during the same period in which lean mass starts to decline, making the ability to retain and respond to muscle an increasingly practical health outcome. In previously untrained adults over age 50, most of whom were women, six weeks of resistance training improved muscle performance in both groups, while hydrogen-rich water produced greater reductions in biomarkers of exercise-induced muscle damage. In an experimental exercise model, H₂ also reduced oxidative stress without suppressing several of the PGC-1α- and TFAM-associated signals involved in mitochondrial adaptation. That combination is potentially more useful than indiscriminately suppressing the physiological stress of exercise, because resistance training itself remains one of the signals the body needs in order to preserve muscle.
The case for H₂ in perimenopause is therefore narrower than a symptom-by-symptom treatment claim, but biologically more coherent. The hormonal transition occurs upstream. Downstream, bone has to remodel under lower estrogen exposure, metabolism has to accommodate changing body composition, mitochondria have to continue matching cellular energy demand, blood vessels have to regulate tone, and muscle has to retain its capacity to adapt to exercise. H₂ has demonstrated measurable changes at several of those downstream points, with the estrogen-withdrawal bone studies providing the strongest direct evidence and the human metabolic, mitochondrial, vascular, sleep, and exercise studies extending the biological plausibility.
What remains missing is the clinical bridge. H₂ has not yet been shown to reduce hot flashes, alter the timing of menopause, preserve bone in perimenopausal women, prevent the redistribution of body fat, or improve perimenopausal sleep specifically. Direct trials would need to measure those outcomes rather than assuming that results from other populations automatically carry over. For now, the evidence suggests that H₂ may influence how some tissues respond to the physiological changes accompanying the menopausal transition, even when it does not change the hormonal transition itself.
References
· Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson-Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., Thurston, R. C., & Study of Women's Health Across the Nation (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA internal medicine, 175(4), 531–539. https://doi.org/10.1001/jamainternmed.2014.8063
· Chaoqun, L., Yuqi, Z., Shi, Z., Zhenghui, Y., & Li, W. (2021). A Comparison of the Antioxidant Effects Between Hydrogen Gas Inhalation and Vitamin C Supplementation in Response to a 60-Min Treadmill Exercise in Rat Gastrocnemius Muscle. Frontiers in physiology, 12, 745194. https://doi.org/10.3389/fphys.2021.745194
· El Khoudary, S. R., Aggarwal, B., Beckie, T. M., Hodis, H. N., Johnson, A. E., Langer, R. D., Limacher, M. C., Manson, J. E., Stefanick, M. L., Allison, M. A., & American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing (2020). Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 142(25), e506–e532. https://doi.org/10.1161/CIR.0000000000000912
· Gao, Y. H., Chen, J., Zhong, H., & Zhao, Q. (2026). Effect of hydrogen-oxygen inhalation on sleep disorders and abnormal mood: a single-blind, randomized controlled trial. Medical gas research, 16(2), 98–102. https://doi.org/10.4103/mgr.MEDGASRES-D-25-00020
· Greendale, G. A., Sowers, M., Han, W., Huang, M. H., Finkelstein, J. S., Crandall, C. J., Lee, J. S., & Karlamangla, A. S. (2012). Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 27(1), 111–118. https://doi.org/10.1002/jbmr.534
· Greendale, G. A., Sternfeld, B., Huang, M., Han, W., Karvonen-Gutierrez, C., Ruppert, K., Cauley, J. A., Finkelstein, J. S., Jiang, S. F., & Karlamangla, A. S. (2019). Changes in body composition and weight during the menopause transition. JCI insight, 4(5), e124865. https://doi.org/10.1172/jci.insight.124865
· Guo, J. D., Li, L., Shi, Y. M., Wang, H. D., & Hou, S. X. (2013). Hydrogen water consumption prevents osteopenia in ovariectomized rats. British journal of pharmacology, 168(6), 1412–1420. https://doi.org/10.1111/bph.12036
· Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., de Villiers, T. J., & STRAW + 10 Collaborative Group (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. The Journal of clinical endocrinology and metabolism, 97(4), 1159–1168. https://doi.org/10.1210/jc.2011-3362
· Ishibashi, T., Kawamoto, K., Matsuno, K., Ishihara, G., Baba, T., & Komori, N. (2020). Peripheral endothelial function can be improved by daily consumption of water containing over 7 ppm of dissolved hydrogen: A randomized controlled trial. PloS one, 15(5), e0233484. https://doi.org/10.1371/journal.pone.0233484
· Korovljev, D., Trivic, T., Drid, P., & Ostojic, S. M. (2018). Molecular hydrogen affects body composition, metabolic profiles, and mitochondrial function in middle-aged overweight women. Irish journal of medical science, 187(1), 85–89. https://doi.org/10.1007/s11845-017-1638-4
· Kuzmanovic, J., Todorovic, N., Ranisavljev, M., Javorac, D., Korovljev, D., Tarnava, A., Stajer, V., & Ostojic, S. M. (2025). The effects of drinking hydrogen-rich water for six weeks on exercise-related biomarkers in exercise-naïve men and women over 50 years following resistance training program: a randomized controlled pilot trial. Research in sports medicine (Print), 33(6), 711–721. https://doi.org/10.1080/15438627.2025.2521474
· LeBaron, T. W., Singh, R. B., Fatima, G., Kartikey, K., Sharma, J. P., Ostojic, S. M., Gvozdjakova, A., Kura, B., Noda, M., Mojto, V., Niaz, M. A., & Slezak, J. (2020). The Effects of 24-Week, High-Concentration Hydrogen-Rich Water on Body Composition, Blood Lipid Profiles and Inflammation Biomarkers in Men and Women with Metabolic Syndrome: A Randomized Controlled Trial. Diabetes, metabolic syndrome and obesity : targets and therapy, 13, 889–896. https://doi.org/10.2147/DMSO.S240122
· Mizuno, K., Sasaki, A. T., Ebisu, K., Tajima, K., Kajimoto, O., Nojima, J., Kuratsune, H., Hori, H., & Watanabe, Y. (2018). Hydrogen-rich water for improvements of mood, anxiety, and autonomic nerve function in daily life. Medical gas research, 7(4), 247–255. https://doi.org/10.4103/2045-9912.222448
· Pula, I., & Yam, E. (2025, June 12). From weight-loss drugs to raw milk, Americans hear more often about some health topics than others. Pew Research Center. https://www.pewresearch.org/short-reads/2025/06/12/from-weight-loss-drugs-to-raw-milk-americans-hear-more-often-about-some-health-topics-than-others/
· Sakai, T., Sato, B., Hara, K., Hara, Y., Naritomi, Y., Koyanagi, S., Hara, H., Nagao, T., & Ishibashi, T. (2014). Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function. Vascular health and risk management, 10, 591–597. https://doi.org/10.2147/VHRM.S68844
· Santoro N. (2016). Perimenopause: From Research to Practice. Journal of women's health (2002), 25(4), 332–339. https://doi.org/10.1089/jwh.2015.5556
· Sumbalová, Z., Kucharská, J., Rausová, Z., Gvozdjáková, A., Szántová, M., Kura, B., Mojto, V., & Slezák, J. (2023). The Effect of Adjuvant Therapy with Molecular Hydrogen on Endogenous Coenzyme Q10 Levels and Platelet Mitochondrial Bioenergetics in Patients with Non-Alcoholic Fatty Liver Disease. International journal of molecular sciences, 24(15), 12477. https://doi.org/10.3390/ijms241512477
· Wu, G., Pan, L., Sun, J., Chen, G., & Wang, S. (2019). Hydrogen gas protects against ovariectomy-induced osteoporosis by inhibiting NF-κB activation. Menopause (New York, N.Y.), 26(7), 785–792. https://doi.org/10.1097/GME.0000000000001310
· Xu, Y., Fergus, D., Hewings-Martin, Y., Hedges, M., Prentice, C., Cunningham, A., Zhaunova, L., Shufelt, C., & Faubion, S. (2026). Exploring prevalence and drivers of perimenopause uncertainty among US Women: a mixed-methods study. Menopause (New York, N.Y.), 10.1097/GME.0000000000002837. Advance online publication. https://doi.org/10.1097/GME.0000000000002837
